$Comparative analysis of mineralocorticoid receptor antagonists and renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitor in heart failure with mildly reduced ejection fraction$

Comparative analysis of mineralocorticoid receptor antagonists and renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitor in heart failure with mildly reduced ejection fraction

IntroductionTo clarify the efficacy of mineralocorticoid receptor antagonists (MRA) and renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors (RASI/ARNI) in heart failure with mildly reduced ejection fraction (HFmrEF).MethodsThis study assessed the association between these...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chia-Chen Lee, David Te-Wei Kuan, Kai-Chun Chang, Zheng-Wei Chen, Jen-Fang Cheng, Ting-Tse Lin, Lian-Yu Lin, Cho-Kai Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Pharmacology
Subjects:	HFmrEF cardiovascular outcomes reninangiotensin system inhibitor angiotensin receptor neprilysin inhibitor MRA (magnetic resonance angiography)
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1507326/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
by: M. O.E. Irhuma, et al.
Published: (2016-11-01)

Angiotensin receptor‐neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction
by: Dong‐Hyuk Cho, et al.
Published: (2025-02-01)

The impact of angiotensin-receptor neprilysin inhibitors on cardiovascular events and solute transport function in peritoneal dialysis patients: a multicenter retrospective controlled study
by: Yishu Wang, et al.
Published: (2024-12-01)

Impact of the angiotensin receptor-neprilysin inhibitor on chronic heart failure due to adult congenital heart disease: A systematic review and meta-analysis
by: Bibhuti B. Das, MD, MBA, MHA, et al.
Published: (2025-05-01)

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
by: A. S. Ryazanov, et al.
Published: (2023-01-01)

Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications
by: Xinyue Zhang, et al.
Published: (2024-12-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

Angiotensin Receptor–Neprilysin Inhibition (Sacubitril/Valsartan) Reduces Structural Arterial Stiffness in Middle‐Aged Mice
by: Isabel N. Schellinger, et al.
Published: (2024-02-01)

Zastosowanie empagliflozyny w leczeniu niewydolności serca z łagodnie obniżoną frakcją wyrzutową lewej komory (HFmrEF) u 40-letniego mężczyzny
by: Agnieszka Karolina Major, et al.
Published: (2025-03-01)

Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study
by: Kathleen Connolly, et al.
Published: (2024-08-01)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
by: Rolf Wachter, et al.
Published: (2020-06-01)

Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
by: Kengo Ayabe, et al.
Published: (2024-10-01)

Impact of Different Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blocker Resumption Timing on Post Acute Kidney Injury Outcomes
by: Jia-Jin Chen, et al.
Published: (2024-11-01)

Prognostic Implications of Sex in Patients With Heart Failure With Mildly Reduced Ejection Fraction: Results From a Large‐Scaled Registry
by: Marielen Reinhardt, et al.
Published: (2025-01-01)

A higher mortality in men compared to women with heart failure in primary care and ejection fraction equal to or more than 40%
by: Björn Eriksson, et al.
Published: (2024-12-01)

Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction
by: Xiaogang Zhu, et al.
Published: (2024-01-01)

Polymorphism of renin — angiotensin system genes in progression of liver fibrosis in patients with chronic hepatitis C
by: O. V. Taratina, et al.
Published: (2014-08-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Is Associated With a Reduced Risk of Poststroke Epilepsy in Patients With Ischemic Stroke
by: Kuo‐Cheng Chang, et al.
Published: (2024-09-01)

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-05-01)

Phenotyping patients with chronic obstructive pulmonary disease and heart failure
by: Peter Moritz Becher, et al.
Published: (2025-04-01)

Correction: Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-07-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection
by: Erika Hishida, et al.
Published: (2024-10-01)

Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis
by: Danilo Menichelli, et al.
Published: (2025-06-01)

Angiotensin Receptor‐Neprilysin Inhibitor Is Associated With Improved Cardiac Autonomic Function in Heart Failure
by: Andreas A. Boehmer, et al.
Published: (2024-08-01)

Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19
by: O. M. Drapkina, et al.
Published: (2020-07-01)

Angiotensin-Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers in Older Patients with acute Myocardial Infarction after a Successful Stent Implantation
by: Geum Ko, et al.
Published: (2025-06-01)

Potential renoprotective effects and possible underlying mechanisms of angiotensin receptor-neprilysin inhibitors in cardiorenal syndrome
by: Md. Moshiur Rahman, et al.
Published: (2025-01-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES
by: E. M. Khurs, et al.
Published: (2016-01-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

The use of angiotensin-converting enzyme inhibitors in general medicine
by: M.L.I. Mashitisho
Published: (2012-08-01)

PROSPECTIVE COMPARISON OF ARNI [ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR] WITH ACEI [ANGIOTENSIN CONVERTING-ENZYME INHIBITOR] TO DETERMINE IMPACT ON GLOBAL MORTALITY AND MORBIDITY IN HEART FAILURE TRIAL
Published: (2016-02-01)

Effect of Angiotensin Receptor-neprilysin Inhibitor on Acute Kidney Injury in Patients With Acute Decompensated Heart Failure
by: Gonghao Li, et al.
Published: (2024-03-01)

Non‐genetic factors associated with ACE‐inhibitor and angiotensin receptor blocker‐induced angioedema
by: Diana Dubrall, et al.
Published: (2025-05-01)

Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients
by: Ali Kaan Güren, et al.
Published: (2025-04-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2012-09-01)